A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults
Summary
The main aim of this study is to find out how zasocitinib (TAK-279) interacts with other medicines taken by mouth (orally). This will be examined by how the body processes medicines, which is called pharmacokinetics or PK. In this study, other medicines that will be administered together with zasocitinib include a contraceptive (levonorgestrel (LNG) and ethinyl estradiol \[EE\]), a medicine for diabetes (metformin), a medicine used for heart problems (digoxin), and a medicine that blocks the production of stomach acid (esomeprazole). Another aim is to learn about the side effects of zasocitinib and how well it is tolerated when taken alone and together with these other medicines. During the study, participants will need to stay at the clinic for up to 27 days.
Timeline
- Start
- 2025-01-23
- Primary completion
- 2025-03-11
- Completion
- 2025-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Digoxin | Other / unclassified | — | Oral |
| Subject | Esomeprazole | Small molecule | — | Oral |
| Subject | Levonorgestrel | Small molecule | — | Oral |
| Subject | Metformin | Small molecule | — | Oral |
| Subject | Zasocitinib | Small molecule | — | Oral |
| Subject | ethinyl estradiol | Small molecule | — | Oral |
Indications
No indication recorded.